To evaluate the efficacy of sclerotherapy for congenital vascular malformation (CVM) using a combination of polidocanol foam and bleomycin liquid.
Methods
A retrospective review of a prospectively collected data on patients who had sclerotherapy for CVM from May 2015 to July 2022 was performed.
Results
A total of 210 patients with a mean age of 24.8 ± 2.0 years were included. Venous malformation (VM) was the most common type of CVM, accounting for 81.9% (172/210) of all patients. At 6 months follow-up, the overall clinical effective rate was 93.3% (196/210), and 50% (105/210) of patients were clinically cured. The clinical effective rates in VM, lymphatic, and arteriovenous malformation group were 94.2%, 100%, and 100%.
Conclusion
Sclerotherapy using a combination of polidocanol foam and bleomycin liquid is an effective and safe treatment for venous and lymphatic malformations. It is a promising treatment option with satisfactory clinical outcome in arteriovenous malformations.
Martinez-LopezASalvador-RodriguezLMontero-VilchezT, et al.Vascular malformations syndromes: an update. Curr Opin Pediatr2019; 31(6): 747–753.
2.
KrowchukDPFriedenIJManciniAJ, et al.Clinical practice guideline for the management of infantile hemangiomas. Pediatrics2019; 143(1): e20183475.
3.
WongMParsiKMyersK, et al.Sclerotherapy of lower limb veins: indications, contraindications and treatment strategies to prevent complications - A consensus document of the International Union of Phlebology-2023. Phlebology2023; 38(4): 205–258.
4.
PuigSCasatiBStaudenherzA, et al.Vascular low-flow malformations in children: current concepts for classification, diagnosis and therapy. Eur J Radiol2005; 53: 35–45.
5.
YakesWFVogelzangRLIvancevK, et al.New arteriographic classification of AVM based on the Yakes classification system. In: KimYWLeeBBYakesW, et al. (eds). Congenital vascular malformations. Berlin: Springer, 2017, pp. 63–69.
6.
GriauzdeJWilseckZMChaudharyN, et al.Endovascular Treatment Of Arteriovenous Malformations Of The Head And Neck: Focus On The Yakes Classification And Outcomes. J Vasc Interv Radiol2020; 31(11): 1810–1816.
7.
Hamel-DesnosCAllaertFA. Liquid versus foam sclerotherapy. Phlebology2009; 24(6): 240–246.
8.
ÇayFAltunbulakAYÖzbayY, et al.Clinical results of polidocanol sclerotherapy in venous malformation treatment: Patient-perceived improvement and satisfaction. Phlebology2023; 38(1): 36–43.
9.
YangXChenHGuH, et al.Interim results of bleomycin-polidocanol foam sclerotherapy as a highly efficient technique for venous malformations. J Vasc Surg Venous Lymphat Disord2020; 8(6): 1066–1073.
10.
MarkovicJNNagUShortellCK. Safety and efficacy of foam sclerotherapy for treatment of low-flow vascular malformations in children. J Vasc Surg Venous Lymphat Disord2020; 8(6): 1074–1082.
11.
AnhTTNguyenQLThiQM, et al.Digital subtraction angiography-guided foam sclerotherapy with polidocanol for treating superficial venous malformation. Ann Vasc Dis2021; 14(3): 231–235.
12.
SachinKRashmiSManishS, et al.Haemangiomas and venous malformations of the head and neck: a retrospective analysis of endovascular management in 358 patients. Indian J Plast Surg2013; 46(1): 109–116.
13.
O'DonovanJCDonaldsonJSMorelloFP, et al.Symptomatic hemangiomas and venous malformations in infants, children, and young adults: treatment with percutaneous injection of sodium tetradecyl sulfate. AJR Am J Roentgenol1997; 169(3): 723–729.
14.
HassanYOsmanAKAltyebA. Noninvasive management of hemangioma and vascular malformation using intralesional bleomycin injection. Ann Plast Surg2013; 70(1): 70–73.
15.
LiLFengJZengXQ, et al.Fluoroscopy-guided foam sclerotherapy with sodium morrhuate for peripheral venous malformations: Preliminary experience. J Vasc Surg. 2009;49(4):961–967.
16.
KhungerNSacchidanandS. Standard guidelines for care: sclerotherapy in dermatology. Indian J Dermatol Venereol Leprol. 2011;77(2):222–231.
17.
PascarellaLBerganJJYamadaC, et al.Venous angiomata: treatment with sclerosant foam. Ann Vasc Surg2005; 19(4): 457–464.
18.
de Ávila OliveiraRRieraRVasconcelosV, et al.Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev. 2021;12(12):CD001732.
19.
BreuFXGuggenbichlerSWollmannJC. 2nd European consensus meeting on foam sclerotherapy 2006, Tegernsee, Germany. Vasa. 2008;37Suppl 71:1–29.
20.
BlaiseSCharavin-CocuzzaMRiomH, et al.Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review. Eur J Vasc Endovasc Surg2011; 41(3): 412–417.
21.
MimuraHKanazawaSYasuiK, et al.Percutaneous sclerotherapy for venous malformations using polidocanol under fluoroscopy. Acta Med Okayama2003; 57(5): 227–234.
22.
RabeEBreuFXCavezziA, et al.Guideline group. European guidelines for sclerotherapy in chronic venous disorders. Phlebology2014; 29(6): 338–354.
23.
De MaeseneerMGKakkosSKAherneT, et al.Editor's Choice - european society for vascular surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg2022; 63(2): 184–267.
PinheiroMCarreiraMRocha-NevesJ. Management of the upper limb arteriovenous malformations. Port J Card Thorac Vasc Surg2022; 29(1): 45–51.
26.
CastrénEAronniemiJKlockarsT, et al.Complications of sclerotherapy for 75 head and neck venous malformations. Eur Arch Otorhinolaryngol2016; 273(4): 1027–1036.
27.
DuffyDM. Sclerosants: a comparative review. Dermatol Surg2010; 36(Suppl 2): 1010–1025.
28.
GuexJJ. Complications and side-effects of foam sclerotherapy. Phlebology2009; 24(6): 270–274.
